// App-Quantinova.ai

BSH19‐PO‐102 : Safety of delivery of bortezomib to patients with cardiac AL Amyloidosis: The impact of cardiac monitoring

Researchers

Presenter

  • C. Attwood

Principal Investigators

  • D. Sado

  • C. Rice

  • M. Streetly

  • I. El-Najjar

  • A. Wechalekar

  • D. Gunning

  • S. Deppe

  • R. Benjamin

  • K. Cuthill

Medical Centers

  • Hematology

  • Cardiology, King's College Hospital NHS Foundation Trust

  • Guy’s and St. Thomas’ NHS Foundation Trust

  • Department of Urology, King's College Hospital NHS Foundation Trust, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Cardiovascular (CVS)

  • Genetic Disorder

  • Oncology (ONC)

Disease

  • Cardiac arrest

  • Multiple Myeloma

  • Renal insufficiency

  • AL Amyloidosis

  • Amyloid disease

Biomarkers

  • N/A

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Amiodarone Hydrochloride

  • Bortezomib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved